Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)

NCT01527279 is registered in ClinicalTrials.gov with National Institute of Cardiology, Warsaw, Poland as lead sponsor.

NCT NCT01527279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01527279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2012
Completion date
March 31, 2015
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation